Surrogate endpoints in clinical trials: cardiovascular diseases.
about
What are biomarkers?Biomarkers and surrogate endpointsA simple method for analyzing data from a randomized trial with a missing binary outcomeCarotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitorsEndpoints in stem cell trials in ischemic heart failureLong-term drug prevention trials.Test the reliability of doubly robust estimation with missing response data.Enhancing prescription drug innovation and adoptionImpact of medical therapy on atheroma volume measured by different cardiovascular imaging modalitiesOutcomes in registered, ongoing randomized controlled trials of patient education.The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.Surrogate end points in heart failure.A new estimation with minimum trace of asymptotic covariance matrix for incomplete longitudinal data with a surrogate process.Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.govThe Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease.Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onsetSurrogate end points in pulmonary arterial hypertension: assessing the response to therapy.New developments in medical clinical trials.Research priorities in biomarkers and surrogate end-points.Robust estimation of the proportion of treatment effect explained by surrogate marker informationThe Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogatAccounting for treatment by center interaction in sample size determinations and the use of surrogate outcomes in the pessary for the prevention of preterm birth trial: a simulation studyC-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn's disease.Patient-important outcomes in randomized controlled trials in critically ill patients: a systematic review.From bad pharma to good pharma: aligning market forces with good and trustworthy practices through accreditation, certification, and rating.Biomarkers-A General Review.A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?Surrogate markers for assessing treatment response in HIV disease.Global rank tests for multiple, possibly censored, outcomesSurrogate end points in clinical trials.The evaluation of multiple surrogate endpoints.Innovative designs in behavioural trials.Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?A comparison of imputation strategies in cluster randomized trials with missing binary outcomes.Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
P2860
Q24613362-1D743445-ABDC-420A-8CDF-8010C8FA4C43Q24678760-CCE2D868-0E25-48A1-8248-9957CEB70256Q24800706-4B949A5D-5E76-436E-B03A-BB9F45A2481CQ24803555-6A966D76-44BC-4890-98DB-81CAF855E3F4Q26796330-9D75DEC7-EF2E-4341-BA30-4F08A177AE0FQ30368543-6825ED1C-2CBD-47F7-9DD0-6D91598B531BQ30765072-1EE10B1C-032D-4E69-A1AE-02B62CCA99B6Q33725286-CDD812A7-7843-4669-ACD7-AC23BAC670BFQ34018909-01571381-E0C3-4189-8C2C-54098F7A1D6DQ34391137-6436E63D-0D69-40A4-B5E5-E9E82B3BFD1BQ34518494-C68F8428-1D5D-42DE-803E-BFFFBB90982BQ34564309-3E0E41DE-5858-4C41-A966-1A34F67D1C40Q34762367-C454973A-23A6-4560-865C-4721901C2568Q35000520-C192CB18-31F6-4F0A-B677-21FA0D36818DQ35090717-A67960B3-E570-4CD4-A7DC-F944E01377A9Q35143420-57041D2D-C339-4F1A-8B1F-8CA95247B6B6Q35792872-550140D3-AEDA-450C-9018-7AC69BF0DF95Q35852007-D50E09E3-383C-4F58-B176-393F50A1BF6FQ36081463-2C5C89E8-BC74-4372-9753-BDE9D4F847EBQ36784550-64C7E22A-1F4F-4E68-BA70-CB255F5F8952Q36966415-0F2634B7-470D-4309-A5E2-E7215A3F5C39Q37064401-69430941-E578-4B5E-9DE0-3974BB2C81D2Q37164209-328AF572-A946-494D-8264-F32CBB0DA577Q37685427-E6109608-ECE7-4743-B81F-C3FDFDFA2210Q38148606-E75E056D-B223-4696-9BF5-BC1C769A46D3Q39183771-802F887C-DFB3-430B-BFDB-42F13CC71466Q39451637-E122F54C-BC31-434E-9F87-8E05CFF52064Q40709551-1F73B3F4-09C8-4820-9239-51C5582541BAQ41943653-D83AF9BC-86AC-494B-B6ED-CA7FD674C054Q42781362-AC491C7F-D232-407E-9063-3459C4E43399Q43544469-D3D735F5-C04B-4697-81E0-6ABE14588B67Q44153774-14C7804D-C84B-4BED-8857-7E48D3EA852EQ44634074-87370594-E924-4B75-B7DF-5A5E1D6ED504Q44688920-8B71F0EE-C0DC-46C9-8F35-D8B02E1AD321Q45906671-65855315-A7BE-485A-A91C-7E7980BD384DQ46692197-459D3054-78E4-4E10-9D4D-41FFC738E6B6Q52644314-9FB34722-F456-47FE-AC22-B2D580EDB857
P2860
Surrogate endpoints in clinical trials: cardiovascular diseases.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Surrogate endpoints in clinical trials: cardiovascular diseases.
@en
Surrogate endpoints in clinical trials: cardiovascular diseases.
@nl
type
label
Surrogate endpoints in clinical trials: cardiovascular diseases.
@en
Surrogate endpoints in clinical trials: cardiovascular diseases.
@nl
prefLabel
Surrogate endpoints in clinical trials: cardiovascular diseases.
@en
Surrogate endpoints in clinical trials: cardiovascular diseases.
@nl
P2093
P356
P1476
Surrogate endpoints in clinical trials: cardiovascular diseases.
@en
P2093
Probstfield J
P304
P356
10.1002/SIM.4780080405
P407
P577
1989-04-01T00:00:00Z